Background: The aetiology of chronic urticaria is heterogeneous. Physical urticaria (PU) is estimated at around 35%, autoimmune urticaria (AIU) at 25% and chronic idiopathic urticaria (CIU) at 35% of all chronic urticaria cases.

Methods: Differences in clinical and laboratory parameters among AIU, PU and CIU groups were examined. AIU was diagnosed if the basophil CD63 assay was positive. Demographic data, severity of symptoms and association with allergic and autoimmune diseases were analysed by the aid of a questionnaire. Immunoassays were carried out and the effectiveness of therapy was also investigated.

Results: Concerning the urticaria score, AIU patients had significantly higher total urticaria scores than patients with CIU (p = 0.013), dermatographic urticaria (p = 0.05) or cholinergic urticaria (p = 0.038). Between CIU and dermatographic urticaria and between CIU and cholinergic urticaria patients, we found insignificant differences in the urticaria score (p = 0.707 and p = 0.336, respectively). AIU was more frequently associated with autoimmune diseases in the personal history (p < 0.001) and with other types of urticaria in the family history (p < 0.001). Also, anti-thyroid antibodies were more frequently detected in the AIU group. Antihistamine therapy was less effective in the AIU group (12.8%) than in the PU (70.3%) and CIU groups (68.6%), but there were no significant differences between the CIU and PU groups regarding the effectiveness of antihistamine therapy.

Conclusion: The autoimmune subgroup represents the most severe form of chronic urticaria. On the other hand, there were no significant differences between the CIU and PU groups neither in urticaria scores nor in response to antihistamine therapy.

Download full-text PDF

Source
http://dx.doi.org/10.1159/000103995DOI Listing

Publication Analysis

Top Keywords

urticaria
16
chronic urticaria
16
ciu groups
16
clinical laboratory
8
ciu
8
urticaria ciu
8
autoimmune diseases
8
urticaria score
8
urticaria scores
8
dermatographic urticaria
8

Similar Publications

A Case of Ramipril-Induced Angioedema and Solar Purpura.

Adv Skin Wound Care

January 2025

In the Department of Dermatology, Faculty of Medicine, Sakarya University, Turkey, Rabia Oztas Kara, MD, is Assistant Professor and Bahar Sevimli Dikicier, MD, is Associate Professor. In the Department of Pathology, Bilge Elcin, MD, is Specialist.

This case report describes a patient who developed solar purpura after treatment for angioedema associated with ramipril, an angiotensin-converting enzyme inhibitor. The patient presented to the ED with angioedema. She had been using ramipril for 2 years.

View Article and Find Full Text PDF

A study on the clinical manifestations in lepidopterism.

Arch Dermatol Res

January 2025

Department of Dermatology, Venereology and Leprosy, Sree Uthradom Thirunal Academy Of Medical Sciences, Trivandrum, 695028, India.

Background: Exposure to hairs of caterpillars and moths are collectively termed as lepidopterism. Clinical manifestations include cutaneous presentation of localized stinging reaction with wheals or vesiculation, acute urticarial papules and plaques, ophthalmic, oropharyngeal involvement to severe life-threatening anaphylactic reactions with angioedema.

Aims: In this study we have determined the prevalence of various cutaneous, oropharyngeal and ophthalmic manifestations of lepidopterism at a tertiary health care center.

View Article and Find Full Text PDF

Addictive behavior is not a comorbidity of chronic spontaneous urticaria.

Allergol Int

January 2025

Institute of Allergology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany; Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Immunology and Allergology, Berlin, Germany.

View Article and Find Full Text PDF

Background: Topical steroids are widely used in dermatology for their anti-inflammatory and immunosuppressive effects, but misuse can cause skin thinning and systemic issues. In Ethiopia, where skin conditions are common, understanding how topical steroids are prescribed and used is essential for ensuring their safe and effective use.

Objective: The study aimed to assess topical steroids' prescription and utilization pattern in Dessie Comprehensive Specialized Hospital (DCSH) from February 1 to May 30, 2024.

View Article and Find Full Text PDF

Background: This study compared the therapeutic equivalence of CT-P39 (an omalizumab biosimilar) and EU-approved reference omalizumab (ref-OMA) in patients with chronic spontaneous urticaria.

Methods: This double-blind, randomized, active-controlled Phase 3 study (NCT04426890) included two 12-week treatment periods (TPs). In TP1, patients received CT-P39 300 mg, ref-OMA 300 mg, CT-P39 150 mg, or ref-OMA 150 mg.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!